Citius Pharmaceuticals reaches milestone in clinical trial of Mino-Lok solution

Citius Pharmaceuticals has reached a milestone in its clinical trial for Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. Pending confirmation, the company believes all 92 events required to complete the trial have been achieved. Several patients remain in active treatment, which may result in additional events. The Phase 3 pivotal superiority trial is a blinded study to determine the efficacy and safety of Mino-Lok, a novel antibiotic lock therapy that combines minocycline with edetate disodium. The primary endpoint for this study is the time to a catheter failure event between randomization and TOC in the Intent-to-Treat Population. Additional secondary outcome measures include overall success, microbiological eradication, and clinical cure, among others.